menu
    • menu
    [{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"MAX001","moa":"GPCR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Maxion Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Maxion Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"4","companyTruncated":"Maxion Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Votucalis","moa":"Histamine","graph1":"Dermatology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.51000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Sanofi"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Maxion Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Maxion Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAX001

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : General Catalyst

                            Deal Size : $72.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Maxion Raises $72M Series A to Advance KnotBody® Pipeline And Platform

                            Details : Proceeds will be used to transform Maxion into a clinical-stage biotech company, taking the lead KnotBody programme MAX001. It is being evaluated for atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 17, 2025

                            Lead Product(s) : MAX001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : General Catalyst

                            Deal Size : $72.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lindus Health

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Lindus Health

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha-Cyclodextrin

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Acinonyx Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lindus Health Launches Acne Trial with Acinonyx Bio Evaluating Alternative Treatment

                            Details : The collaboration aims to conduct the clinical development of ACX, which is evaluating their topical cream's ability to treat patients with moderate to severe inflammatory acne.

                            Product Name : ACX

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Alpha-Cyclodextrin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Acinonyx Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            LifeArc Portfolio Company Ducentis Bio Therapeutics Acquired by Arcutis Biotherapeutics for Up to $400 Million

                            Details : DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $16.0 million

                            September 08, 2022

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Ducentis BioTherapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

                            Details : DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $16.0 million

                            September 07, 2022

                            Lead Product(s) : DS-234

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Arcutis Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sareum

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sareum

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SDC-1801

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sareum Submits Clinical Trial Authorisation Application to UK MHRA for Development of TYK2/JAK1 Inhibitor SDC-...

                            Details : SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2022

                            Lead Product(s) : SDC-1801

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akari Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Akari Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Votucalis

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat ...

                            Details : Votucalis is a broad-acting histamine inhibitor that was discovered through the same research program that yielded Akari’s lead drug, nomacopan, a complement and leukotriene inhibitor currently in Phase III clinical development.

                            Product Name : Votucalis

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 09, 2022

                            Lead Product(s) : Votucalis

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            C4X Discovery

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            C4X Discovery

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $505.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Up to €414 Million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A Inhibitor Progra...

                            Details : Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases. The IL-17 family of cytokines are inducers of inflammation in variety of autoimmune diseases including psoriasis, psoriatic arthritis & a...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $7.3 million

                            April 12, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $505.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth